Progress of cellular and vaccine immunotherapy in multiple myeloma
10.3760/cma.j.issn.1009-9921.2017.02.008
- VernacularTitle:细胞及疫苗免疫疗法在多发性骨髓瘤中的研究进展
- Author:
Jun HOU
;
Yuanyuan KONG
;
Fenghuang ZHAN
;
Jumei SHI
- Keywords:
Multiple myeloma;
Cellular immunotherapy;
Vaccine immunotherapy;
American Society of Hematology Annual Meeting
- From:
Journal of Leukemia & Lymphoma
2017;26(2):86-90
- CountryChina
- Language:Chinese
-
Abstract:
Allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusion for multiple myeloma (MM) can induce graft-versus-myeloma immunity and long-term survival,but limited efficacy and associated toxicities have prevented its widespread application.Cellular immunotherapies and vaccines are explored to induce more specific,reliable,and potent antimyeloma immune responses with less treatmentrelated risk.Advances in molecular biology,basic and applied immunology,have led to several promising approaches such as genetically engineered T cells with chimeric antigen receptors and T-cell receptors targeting myeloma-specific epitopes,vaccine primed ex vivo expanded autologous T cells,expanded marrowinfiltrating lymphocytes,and plasma cell/dendritic cell fusion vaccines.The combination of these emerging therapies to immunomodulatory drugs and inhibitors of programmed death-1 T-cell regulatory pathways could improve the outcome for MM patients.This article reviews the latest progress of cellular and vaccine immunotherapy for MM at the 58th American Society of Hematology (ASH) Annual Meeting,and discusses how these therapies might integrate and synergize with existing treatment paradigms.
